Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Medicines register
Registers Clinical trials Drugs API
Registers› Irish medicines ›Baxter Holding B.V.
Medicines register · Ireland

Baxter Holding B.V. — licensed medicines

74 medicines held by Baxter Holding B.V. on the Irish market, from the HPRA register.

Download CSV
Source: HPRA open dataset ("Authorised or Transfer Pending Products"), CC BY 4.0. Complete coverage — all 10,295 authorised products are in this register. Synced 06 Oct 2026, 03:23 UTC
Narrow the register Reset
Matches brand name, active substance, licence holder and licence number.
Browse by first letter
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9
74 of 10,295 medicines
Download
Medicine
Active substance
Licence holder
Status
Aciclovir 25mg/ml Concentrate for solution for infusion PA2299/041/001
Aciclovir
Baxter Holding B.V.
Not marketed
ARTISS Solutions for Sealant, deep frozen PA2299/026/001
Human fibrinogen, Human thrombin, Calcium chloride, Aprotinin
Baxter Holding B.V.
Marketed
Brevibloc Premixed 10 mg/ml solution for Infusion PA2299/021/002
Esmolol Hydrochloride
Baxter Holding B.V.
Marketed
Brevibloc Premixed 10 mg/ml Solution for Injection PA2299/021/001
Esmolol Hydrochloride
Baxter Holding B.V.
Marketed
Bupivacaine 2.5 mg/ml Solution for Injection PA2299/035/001
Bupivacaine hydrochloride, monohydrate
Baxter Holding B.V.
Not marketed
Bupivacaine 5 mg/ml Solution for Injection PA2299/035/002
Bupivacaine hydrochloride, monohydrate
Baxter Holding B.V.
Marketed
Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion EU/1/96/011/001-004
DOXORUBICIN HYDROCHLORIDE
Baxter Holding B.V.
—
Cernevit, Powder for Solution for Injection or Infusion PA2299/019/001
Retinol palmitate, Cholecalciferol, Dl-a-tocopherol, Ascorbic acid, Cocarboxylase tetrahydrate
Baxter Holding B.V.
Marketed
Chlorhexidine acetate 0.015% w/v and Cetrimide 0.15% w/v Irrigation solution PA2299/005/001
Chlorhexidine acetate, Cetrimide
Baxter Holding B.V.
Not marketed
Chlorhexidine Acetate BP 0.05% w/v Irrigation solution PA2299/004/001
Chlorhexidine acetate
Baxter Holding B.V.
Marketed
CLINIMIX N14G30E, solution for infusion PA2299/020/001
L-leucine, L-phenylalanine, L-methionine, L-isoleucine, L-valine
Baxter Holding B.V.
Marketed
Compound Sodium Lactate Solution for Infusion BP PA2299/012/001
Sodium chloride, Potassium chloride, Calcium chloride dihydrate, Sodium lactate
Baxter Holding B.V.
Marketed
Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion PA2299/050/001
Dexmedetomidine hydrochloride
Baxter Holding B.V.
Not marketed
Endoxana Coated Tablets 50 mg PA2299/027/003
Cyclophosphamide monohydrate
Baxter Holding B.V.
Marketed
Endoxana Injection 1000 mg Powder for Solution for Injection PA2299/027/002
Cyclophosphamide
Baxter Holding B.V.
Marketed
Endoxana Injection 500 mg Powder for Solution for Injection PA2299/027/001
Cyclophosphamide
Baxter Holding B.V.
Marketed
Eribulin Baxter 0.44 mg/mL solution for injection EU/1/24/1819/001
Eribulin mesylate
Baxter Holding B.V.
—
Finomel Emulsion for Infusion PA2299/044/002
Glycine, Alanine, Arginine, Histidine, Isoleucine
Baxter Holding B.V.
Marketed
Finomel Peri Emulsion for Infusion PA2299/044/001
Alanine, Arginine, Glycine, Histidine, Isoleucine
Baxter Holding B.V.
Marketed
Fluconazole 2 mg/ml solution for infusion PA2299/033/001
Fluconazole
Baxter Holding B.V.
Marketed
Furosemide 10 mg/ml Solution for Injection PA2299/036/001
Furosemide
Baxter Holding B.V.
Not marketed
Glucose 10% w/v Solution for Infusion PA2299/003/002
Glucose
Baxter Holding B.V.
Marketed
Glucose 5% w/v Intravenous Infusion BP, polyolefin/polyamide bag PA2299/003/001
Glucose
Baxter Holding B.V.
Marketed
Heparin Sodium BP 1000 IU/l in 0.9% w/v Sodium Chloride IV Infusion PA2299/014/001
Heparin sodium, Sodium chloride, Disodium phosphate dodecahydrate, Citric acid monohydrate
Baxter Holding B.V.
Marketed
Heparin Sodium BP 2000 IU/l in 0.9 % w/v Sodium Chloride IV infusion PA2299/014/002
Citric acid monohydrate, Disodium phosphate dodecahydrate, Sodium chloride, Heparin sodium
Baxter Holding B.V.
Marketed
Maintelyte solution for infusion PA2299/045/001
Sodium chloride, GLUCOSE MONOHYDRATE PH. EUR., Sodium acetate, trihydrate, POTASSIUM CHLORIDE PH. EUR., MAGNESIUM CHLORIDE HEXAHYDRATE PH. EUR.
Baxter Holding B.V.
Marketed
Mannitol 10% Solution for Infusion BP PA2299/006/001
Mannitol
Baxter Holding B.V.
Marketed
Mannitol 15% w/v solution for infusion PA2299/006/002
Mannitol
Baxter Holding B.V.
Marketed
Mitoxana 1 g Powder for Sterile Concentrate PA2299/028/001
Ifosfamide
Baxter Holding B.V.
Marketed
Mitoxana 2 g powder for sterile concentrate PA2299/028/002
Ifosfamide
Baxter Holding B.V.
Marketed
Numeta G13%E Preterm emulsion for infusion PA2299/030/003
Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic acid
Baxter Holding B.V.
Marketed
Numeta G16%E emulsion for infusion PA2299/030/001
Alanine, Arginine, Aspartic Acid, Cysteine, Glutamic acid
Baxter Holding B.V.
Marketed
Numeta G19%E emulsion for infusion PA2299/030/002
Methionine, Ornithine hydrochloride, Phenylalanine, Proline, Serine
Baxter Holding B.V.
Marketed
Ondansetron 2mg/ml Solution for Injection PA2299/037/001
Ondansetron
Baxter Holding B.V.
Marketed
Pemetrexed Baxter 100 mg powder for concentrate for solution for infusion EU/1/22/1705/001
Pemetrexed disodium heptahydrate
Baxter Holding B.V.
—
Pemetrexed Baxter 500 mg powder for concentrate for solution for infusion EU/1/22/1705/002
Pemetrexed disodium heptahydrate
Baxter Holding B.V.
—
Plasma-Lyte 148 & Glucose 5% w/v solution for infusion PA2299/007/001
Glucose monohydrate, Sodium chloride, Potassium chloride, Magnesium chloride hexahydrate, Sodium acetate trihydrate
Baxter Holding B.V.
Marketed
Plasma-Lyte 148 (pH 7.4) solution for infusion PA2299/032/001
Sodium chloride, Potassium chloride, Magnesium chloride hexahydrate, Sodium acetate trihydrate, Sodium gluconate
Baxter Holding B.V.
Marketed
Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for Infusion - BP PA2299/010/002
Potassium chloride, Sodium chloride
Baxter Holding B.V.
Marketed
Potassium Chloride 0.15% w/v and Glucose 5% w/v Solution for Infusion BP PA2299/009/002
Potassium chloride, Glucose
Baxter Holding B.V.
Marketed
Potassium Chloride 0.15% w/v, Sodium Chloride 0.18% w/v, Glucose 4% w/v Solution for Infusion PA2299/001/002
Potassium chloride, Sodium chloride, Glucose anhydrous
Baxter Holding B.V.
Marketed
Potassium Chloride 0.3 % w/v and Glucose 5% w/v Solution for Infusion BP PA2299/009/001
Potassium chloride, Glucose (as monohydrate)
Baxter Holding B.V.
Marketed
Potassium Chloride 0.3% w/v & Sodium Chloride 0.9% w/v Solution for Infusion BP PA2299/010/001
Potassium chloride, Sodium chloride
Baxter Holding B.V.
Marketed
Potassium Chloride 0.3% w/v and Sodium Chloride 0.18% w/v in Glucose 4% w/v Intravenous Infusion BP (Viaflo Container) PA2299/001/001
Potassium chloride, Sodium chloride, Glucose monohydrate
Baxter Holding B.V.
Marketed
Primene 10% Solution for Infusion PA2299/018/001
L-isoleucine, L-leucine, L-valine, L-lysine, L-methionine
Baxter Holding B.V.
Marketed
Propofol 10 mg/ml Emulsion for injection/infusion PA2299/038/001
Propofol
Baxter Holding B.V.
Marketed
Propofol 20 mg/ml Emulsion for injection/infusion PA2299/038/002
Propofol
Baxter Holding B.V.
Marketed
Ringer’s Solution for Infusion, Viaflo container PA2299/011/001
Sodium chloride, Potassium chloride, Calcium chloride dihydrate
Baxter Holding B.V.
Marketed
Sevoflurane Baxter, 100%, inhalation vapour, liquid PA2299/031/001
Sevoflurane
Baxter Holding B.V.
Marketed
Sodium Chloride 0.18% w/v and Glucose 4.0% w/v Intravenous Infusion BP, (Viaflo Container) PA2299/008/005
Sodium chloride, Anhydrous glucose
Baxter Holding B.V.
Marketed
Showing 1–50 of 74
1 2 Next
Cite this view

Priya Life Science (2026). Irish Medicines Register, filtered. Derived from the HPRA open dataset. Retrieved 6 October 2026. https://priyalifescience.com/medicines/company/baxter-holding-b-v

Download this register
GET /api/export.php?register=medicines-ie&format=csv Try the JSON export →
Regulatory information only — not medical advice. For the authoritative record see the HPRA register directly.